RareCyte Secures $24M Financing
- RareCyte, Inc., WA-based Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, raised $24M in financing
- Arboretum Ventures led the financing joined by other new investors F-Prime Capital, Logos Capital, and Agilent Technologies
- Existing investors participating in the financing included HealthQuest Capital, 5AM Ventures, and Company founder Ron Seubert
- Jan Garfinkle, Arboretum Managing Partner, joined the company Board of Directors along with Robert Weisskoff, Ph.D., Partner at F-Prime Capital
- The company offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics
- The company has deep experience in developing advanced precision life science systems used in labs worldwide
